BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment
Menée in vitro et in vivo, cette étude évalue l'activité antitumorale d'une thérapie génique, activant un gène impliqué dans l'apoptose, en combinaison avec le lapatinib pour le traitement du cancer du sein
Breast cancer initiating cells (BCICs), which can fully recapitulate the tumor origin and are often resistant to chemo- and radiotherapy, are currently considered as a major obstacle for breast cancer treatment. Here, we show that BIKDD, a constitutively active mutant form of proapoptotic gene, BIK, effectively induces apoptosis of breast cancer cells and synergizes with lapatinib. Most importantly, BikDD significantly reduces BCICs through co-antagonism of its binding partners Bcl-2, Bcl-xL, and Mcl-1, suggesting a potential therapeutic strategy targeting BCICs. Furthermore, we developed a cancer-specific targeting approach for breast cancer that selectively expresses BikDD in breast cancer cells including BCICs, and demonstrated its potent antitumor activity and synergism with lapatinib in vitro and in vivo. º Bcl-2 proteins are critical for breast cancer initiating cells (BCICs) survival º BikDD eliminates BCICs through co-antagonism of Bcl-2 antiapoptotic proteins º Development of breast cancer-selective expression vector that also targets BCICs º BikDD sensitizes breast cancer cells to lapatinib